G9420 HCPCS Level II code: Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer
G9420 is the HCPCS code for “Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
G9420Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer
Short description: Spec site no lung
HCPCS · United States
Medicare details
The indicators CMS publishes with G9420 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2015
Where G9420 sits
- 1G codesProcedures and professional services
- 2Active code G9420Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code G9420 mean?
G9420 is the HCPCS code for “Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover G9420?
CMS lists G9420’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside G9420
All G codesG9414Patient had one dose of meningococcal vaccine (serogroups a, c, w, y or a, c, w, y, b) on or between the patient's 10th and 13th birthdaysG9415Patient did not have one dose of meningococcal vaccine (serogroups a, c, w, y or a, c, w, y, b), on or between the patient's 10th and 13th birthdaysG9416Patient had one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdaysG9417Patient did not have one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdaysG9418Primary non-small cell lung cancer lung biopsy and cytology specimen report documents classification into specific histologic type following iaslc guidance or classified as…G9419Documentation of medical reason(s) for not including the histological type or nsclc-nos classification with an explanation (e.g. specimen insufficient or non-diagnostic, specimen…G9421Primary non-small cell lung cancer lung biopsy and cytology specimen report does not document classification into specific histologic type or histologic type does not follow…G9422Primary lung carcinoma resection report documents pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma, adenocarcinoma and…G9423Documentation of medical reason for not including pt category, pn category and histologic type [for patient with appropriate exclusion criteria (e.g., metastatic disease, benign…G9424Specimen site other than anatomic location of lung, or classified as nsclc-nosG9425Primary lung carcinoma resection report does not document pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma…G9426Improvement in median time from ed arrival to initial ed oral or parenteral pain medication administration performed for ed admitted patients